We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Novo Nordisk | NYSE:NVO | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.30 | 0.24% | 123.35 | 123.51 | 121.78 | 122.04 | 846,322 | 15:02:21 |
From May 2019 to May 2024
By Dominic Chopping
Novo Nordisk A/S (NOV) said Monday it is investing DKK1.5 billion in new haemophilia treatment manufacturing facility in Denmark.
The Danish pharmaceutical company said the new facility in Kalundborg, Denmark will produce active pharmaceutical ingredients for its NovoSeven product as well as future products for treating haemophilia.
The investment is estimated to create 100 new production and engineering jobs in Kalundborg, where Novo Nordisk currently employs more than 2,800 people, it said.
The facility is expected to be approved and fully operational in 2020.
-Write to Dominic Chopping at dominic.chopping@wsj.com; Twitter: @WSJNordics
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Novo Nordisk Chart |
1 Month Novo Nordisk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
